Harmony Biosciences Holdings Inc (HRMY)

$29.32 0.39 (1.35%)

16:00 EDT HRMY Stock Quote Delayed 30 Minutes

The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Feb 12, 2024

Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.

The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On

More Articles

Volume:

Previous Close -

Market Cap 1.66B

PE Ratio 13.83

EPS 2.12

Volume (Avg. Vol.) 375,891

Day's Range $29.00 - $30.14

52-Week Range $18.61 - $39.26

Dividend & Yield N/A (N/A)

HRMY Stock Predictions, Articles, and Harmony Biosciences Holdings Inc News

From InvestorPlace
From the Web

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?

By Josh Enomoto, InvestorPlace Contributor Aug 14, 2023

With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications.

7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now

By Josh Enomoto, InvestorPlace Contributor Aug 3, 2023

Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.

7 Best High-Growth Stocks to Buy if You’re a Young Investor

By Josh Enomoto, InvestorPlace Contributor Jun 29, 2023

If you’re just starting out and have plenty of time to work with, these are the high-growth stocks for young investors.

3 Biotech Stocks to Buy With Explosive Upside Potential

By Alex Sirois, InvestorPlace Contributor Jun 22, 2023

These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.

7 Stocks to Buy to Bag Big-Time Returns in Q2

By Josh Enomoto, InvestorPlace Contributor Apr 16, 2023

If you’re willing to take huge risks, these stocks to buy might yield you massive gains in Q2 – or you could be looking at a tax write-off.

7 Biotech Stocks to Buy for 100% Returns

By Josh Enomoto, InvestorPlace Contributor Apr 9, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

HRMY Stock Alert: Scorpion Short Report Sends Harmony Plunging

By Eddie Pan, InvestorPlace Financial News Writer Mar 28, 2023

Scorpion Capital has issued a short report on HRMY stock, alleging that the company's Wakix drug is not safe for the public.

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

By Muslim Farooque, InvestorPlace Contributor Mar 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio

The 7 Best Biotech Stocks to Buy for February 2023

By Josh Enomoto, InvestorPlace Contributor Feb 7, 2023

Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.

7 Healthcare Stocks That Will Be Big Winners in 2023

By Alex Sirois, InvestorPlace Contributor Jan 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

7 No-Brainer Biotech Stocks to Add to Your Buy List

By Josh Enomoto, InvestorPlace Contributor Jun 9, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

3 Desirable Drug Stocks With Very Promising Pipelines

By Larry Ramer, InvestorPlace Contributor Feb 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript

From The Motley Fool Feb 22, 2024

HRMY earnings call for the period ending December 31, 2023.

Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line (NASDAQ:HRMY)

From Seeking Alpha Feb 22, 2024

Harmony Biosciences reports Q4 non-GAAP EPS of $0.73, missing estimates by $0.18.

Harmony gets FDA orphan drug status for Prader-Willi treatment (NASDAQ:HRMY)

From Seeking Alpha Feb 20, 2024

Harmony Biosciences (HRMY) has received orphan drug designation from the FDA for its drug pitolisant in the treatment of Prader-Willi syndrome. Read more here.

NASDAQ:HRMY: good value for what you're paying.

From Chartmill Jan 25, 2024

In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals.

NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.

From Chartmill Jan 10, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.

Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.

From Chartmill Jan 3, 2024

Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.

ADVERTISEMENT